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ARTICLE
A CRISPR platform for targeted in vivo screens
identifies Toxoplasma gondii virulence factors
in mice
Joanna Young 1,4, Caia Dominicus 1,4, Jeanette Wagener1, Simon Butterworth 1, Xingda Ye 1,
Gavin Kelly 2, Merav Ordan1, Becky Saunders3, Rachael Instrell3, Michael Howell 3, Aengus Stewart 2 &
Moritz Treeck 1
Genome-wide CRISPR screening is a powerful tool to identify genes required under selective
conditions. However, the inherent scale of genome-wide libraries can limit their application in
experimental settings where cell numbers are restricted, such as in vivo infections or single
cell analysis. The use of small scale CRISPR libraries targeting gene subsets circumvents this
problem. Here we develop a method for rapid generation of custom guide RNA (gRNA)
libraries using arrayed single-stranded oligonucleotides for reproducible pooled cloning of
CRISPR/Cas9 libraries. We use this system to generate mutant pools of different sizes in the
protozoan parasite Toxoplasma gondi and describe optimised analysis methods for small scale
libraries. An in vivo genetic screen in the murine host identifies novel and known virulence
factors and we confirm results using cloned knock-out parasites. Our study also reveals a
potential trans-rescue of individual knock-out parasites in pools of mutants compared to
homogenous knock-out lines of the key virulence factor MYR1.
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Genetic screens provide significant advances in our under-standing of genes required for growth under variableconditions. The advent of Clustered Randomly Inter-
spersed Short Palindromic Repeats (CRISPR) technology has
supplanted previous gold standard screening methods, and has
enabled the generation of large mutant pools covering the entire
genome of both eukaryotic and prokaryotic organisms1–3. In
addition to identifying genes required for fitness under standard
growth conditions, genetic screens also facilitate the identification
of genes that play a key role under restrictive conditions, such as
under drug pressure or those involved in host–pathogen interac-
tions. For example, genetic screens have provided insights into the
host factors required for bacterial infection (e.g. enterohaemor-
rhagic Escherichia coli and Vibrio parahaemolyticus)4,5, toxin
cytotoxicity6 and viral invasion7. In the parasite Toxoplasma gon-
dii, a genome-wide genetic screen has been used to identify genes
that are required for growth in vitro8. However, CRISPR screens
have not yet been employed, to the best of our knowledge, to
identify virulence factors required during infection of a mamma-
lian host.
Toxoplasma infects virtually any warm-blooded animal,
including 1/3rd of the human population9. Three major Tox-
oplasma clonal lineages have been identified: type I parasites
have a lethal dose (LD) of 1 parasite in laboratory mice (LD100
= 1), while type II and type III strains have a LD50 of 1000 and
>10E5, respectively10. The differences in virulence between
strains are caused by variations in the expression levels or
sequences of parasite virulence factors that are secreted into the
host cell. While several virulence factors have been identified by
genetic crosses between parasite strains11–13, a substantial
proportion of secreted effectors are likely to be required across
all strains and require a different screening approach. Fur-
thermore, some effectors that are essential for virulence in vivo
show no growth defect in cell culture (e.g. GRA214), high-
lighting the importance of in vivo screening for the identifica-
tion of novel factors.
While genome-wide libraries have proven extremely infor-
mative, certain experimental conditions preclude their use. For
instance, target cells may be particularly precious and therefore
cannot be obtained in sufficient numbers to ensure adequate
coverage. Alternatively, the use of large mutant pools may not
be suitable given the nature of the experimental readout such as
in single-cell analyses or, as shown here, in in vivo studies
where the LD of a pathogen dictates the time to select for
phenotypes before overwhelming the host. More specifically,
the dose needs to be sufficiently low to allow parasite replica-
tion without killing the mouse, while maintaining coverage of
the library. In such instances, tailored CRISPR libraries that
target a subset of genes provide a powerful tool. While some
previous studies have used tailored libraries7, these have been
fixed and lacked the option to modify target genes and controls
for each experiment.
Here we have established a method to rapidly generate tailored
CRISPR libraries of varying scale and composition by generating an
arrayed gRNA library for single-step cloning of gRNA pools into a
custom CRISPR/Cas9 vector. We demonstrate reproducible
knockout (KO) efficiency in Toxoplasma using libraries containing
200 to 3200 guides, and establish analysis methods tailored for
small library sizes. Lastly, we demonstrate high reproducibility of
CRISPR screens in vivo, and identify known and novel Tox-
oplasma virulence factors. Surprisingly, we observed that some gene
KOs for virulence factors behave differently when present in a
mutant pool than they do as homogenous clones in murine
infections. The methodology established here provides a versatile
and inexpensive platform for CRISPR library generation that is
widely applicable.
Results
Modified pCas9 plasmid shows robust KO of target genes. To
expand the application of CRISPR screening in Toxoplasma, we
designed a system where customised vector libraries can be
generated by Gibson cloning pools of gRNA sequences into a
common targeting vector. Single-stranded oligonucleotides
encoding gRNAs are arrayed in multiwell plates, and can be
individually selected to use directly for cloning without the need
for hybridisation or amplification steps. The resulting vector
library is transfected into parasites to generate a mutant pool that
is propagated in cell culture for subsequent selection strategies
in vitro or in vivo (Fig. 1a).
While the previously published Toxoplasma genome-wide
guide library targeted the highly virulent type I strain8, type II
strains are most commonly used for in vivo studies. We therefore
designed gRNAs against the full Toxoplasma ME49 (type II)
genome using E-CRISP15, and refined the list based on the
criteria in Supplementary Fig. 1a, to generate 3–5 optimal gRNAs
per gene (Supplementary Data 1). To account for the possibility
of alternative start codons, gRNAs were designed to avoid the first
100 bp, and to reduce truncation (vs. complete KO), gRNAs were
restricted to the first half of the gene. gRNAs targeting the non-
template strand were favoured so the library could also be used
for CRISPRi experiments16. gRNAs targeting 7616 genes were
designed, 7183 genes with 5 gRNAs, and 211 and 222 genes with
4 gRNAs and 3 gRNAs, respectively (Supplementary Fig. 1b).
ME49 gRNA sequences were aligned with the type I GT1 genome
to identify those that can be used in both strains (Supplementary
Data 1).
The previous Toxoplasma CRISPR screen used a parasite line
stably expressing Cas9 and a mock guide to limit Cas9 toxicity,
which was then transfected with the genome-wide gRNA library8.
While this elegantly circumvents the problem of Cas9 toxicity, we
reasoned that expressing the gRNA and Cas9 from a single vector
would both eliminate the need for a mock gRNA, and expand the
range of parasite strains in which this technique could be applied.
We therefore generated a modified CRISPR vector by cloning a
ribosomal skip peptide (T2A) and HXGPRT drug selection
marker in-frame with Cas9-GFP (green fluorescent protein)
(Fig. 1b). As expression of the selectable marker is linked to Cas9
expression, integration of the gRNA-expressing cassette without
simultaneous integration of the Cas9 sequence is precluded. We
introduced a modified tracrRNA sequence previously found to
enhance the stability of the Cas9–gRNA interaction and improve
gene targeting17. The resulting vector pCAS9-T2A-HXGPRT
contains PacI and NcoI restriction sites at the gRNA locus to
allow single-step cloning of single-stranded gRNA-encoding
oligonucleotides. Library generation is highly reproducible as
shown by the correlation of sequencing reads from duplicate
cloning reactions (R2 of 0.9994) (Supplementary Fig. 2A).
To validate the optimised CRISPR plasmid, we targeted the
UPRT gene for disruption. Parasites lacking UPRT are able to
survive in the presence of 5-fluorodeoxyuridine (FUDR). We tested
KO efficiency in both a type I strain, RHΔhxgprt (commonly used
for cell culture experiments), and a type II strain, PruΔhxgprt (used
more frequently for in vivo experiments). Robust KO of UPRT was
observed in both RHΔhxgprt (89%) and PruΔhxgprt (82%), while
no parasites transfected with a control gRNA targeting GRA29 grew
in the presence of FUDR (Fig. 1c). While transfection efficiency was
high (up to 40%), survival rates in transfected populations were low
(1.3% in RHΔhxgprt and 5.3% in PruΔhxgprt (Fig. 1d)). Addition-
ally, the transfection of pCAS9-T2A-HXGPRT plasmid pools
showed a substantial reduction in parasite viability compared to a
single plasmid transfection (RHΔhxgprt 0.25%, PruΔhxgprt 0.72%
survival) (Fig. 1d). We hypothesised that this difference might be
caused by the uptake of multiple plasmids in pooled transfections,
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resulting in multiple double-stranded DNA breaks that the parasites
fail to repair. To investigate this, we performed co-transfections of
plasmids targeting two different, non-essential genes (GRA29 and
UPRT) with either GFP or mCherry fused to Cas9, and quantified
single and double fluorophore expressing parasites. At 24 h post-
transfection of RHΔhxgprt, 65% of parasites were expressing both
fluorophores, which was reduced to 18% after 6 days of drug
selection (Supplementary Fig. 2b). A similar pattern was observed
with PruΔhxgprt (57% at 24 h and 22% after 6 days) (Supplemen-
tary Fig. 2d). While many of these double transfectants will have
died, 36% of RHΔhxgprt and 25% of PruΔhxgprt expressing
mCherry only showed loss of GRA29, which was targeted by the
GFP-expressing plasmid (Supplementary Fig. 2C, D). This indicates
that in pooled transfections, parasites take up multiple gRNA
plasmids causing gene deletions. However, often only one plasmid
is retained and multiple KO events in the same cell will therefore
not be detected by sequencing. While this did not prevent the
generation of reproducible results in our experiments (as shown
further below), it will be a general feature of pooled transfection
strategies. As this impacts parasite survival, it is important that the
number of parasites required to ensure sufficient coverage (i.e.
parasites per gRNA) is calculated using library-specific post-
transfection survival rates, and not standard transfection efficien-
cies. Using the latter would lead to a gross underestimate of the
parasite numbers needed.
Reproducible gene disruption using pooled gRNA libraries. To
assess the reproducibility and the impact of library size and
composition on phenotype scoring, we generated libraries of 210,
810 and 3231 gRNAs (referred to as 200, 800 and 3200 for
simplicity, see Supplementary Data 2). The 200 gRNA library
targets 33 genes encoding non-essential proteins that are pre-
dicted to be secreted, along with 5 essential controls8. The 800
gRNA library, meanwhile, is composed of the 200 gRNA library
supplemented with gRNAs targeting 110 putative or known
Toxoplasma effector proteins. These effectors are rhoptry pro-
teins (ROPs) and dense granule proteins (GRAs), and are secreted
into the parasitophorous vacuole (PV) or into the host cell. The




Arrayed ss gRNA library Selection of gRNA subset
Pooled Gibson assembly
Transfection of linearised plasmid pool
 into Toxoplasma gondii
In vitro growth under M/X selection
Library assembly
Transfection
In vitro/In vivo assays  
In vivo assay
















































Fig. 1 Single-step CRISPR knockout pools from arrayed single-stranded oligos. a Schematic of tailored CRISPR screening method. gRNA encoding
oligonucleotides are arrayed in multiwell plates and the gRNA of interest are selected for pooled Gibson cloning into pCAS9-T2A-HXGPRT. The vector
library is transfected into parasites to generate a pool of mutants for testing in vitro and in vivo. b Schematic of pCAS9-T2A-HXGPRT. Regions of homology
used for Gibson cloning of oligonucleotides are shown in purple. c Gene disruption using integrated pCas9-T2A-HXGPRT. RHΔhxgprt and PruΔhxgprt were
transfected with vectors targeting UPRT or a control gene, GRA29. Transfectants were grown under M/X selection for 6 days before performing a plaque
assay under 5-fluorodeoxyuridine (FUDR) selection to test for UPRT disruption. The percentage of UPRT knockout (KO) was calculated by comparing
plaques numbers in the presence and absence of FUDR. The mean is shown with SD error bars. n= 2 biologically independent experiments. d Parasite
survival is reduced after transfection of plasmid pools. RHΔhxgprt and PruΔhxgprt were transfected with 10 μg pCAS9-T2A-HXGPRT targeting UPRT or a
mixed pool of 1000 gRNA. Parasites were grown in the presence of M/X and the resultant plaques counted after 7 days. The percentage of parasites
surviving compared to parasites seeded was calculated in a plaque assay. The mean is shown with SD error bars. n= 3 biologically independent
experiments. See also Supplementary Fig. 2. Source data are provided as a Source Data file
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fibroblasts8. To test the impact of skewing the library towards
fitness-conferring genes, we expanded the 800 library to target
466 proteins with a signal peptide or a single transmembrane
domain (as these contain an increased proportion of essential
genes), generating the 3200 library. Using the Sidik et al.8 phe-
notype scores associated with these libraries confirms that the
3200 library has a more negative median score than the 200 and
800 libraries (Supplementary Fig. 3). Each gRNA library was
cloned into the pCAS9-T2A-HXGPRT vector, transfected into
PruΔhxgprt (in triplicate) and grown for 6 days to select for
successful integration of the vector. Relative log 2 fold changes
(lfcs) are calculated by comparing gRNA sequence reads from
DNA input and after 6 days of parasite growth in human foreskin
fibroblasts (HFFs). The median of the gRNA lfcs are used to
calculate the gene lfc. This ensures that outliers do not sub-
stantially skew results. The final gene phenotype score is calcu-
lated by taking the average of the gene lfc across replicates
(Supplementary Data 2).
While Sidik et al.8 normalised the total read count per sample
for their genome-wide CRISPR screen, we reasoned that with
smaller library sizes, individual gRNAs that are highly over- or
under-represented may strongly influence normalisation. We
therefore used DEseq218, which uses the median of ratios for
normalisation (the median of each gene’s ratio to the geometric
mean of the sample) and, as such, is less affected by outliers.
Indeed, DEseq2 shows high correlation between the triplicate
transfections for each pool (Fig. 2a), while the total read count
approach does not (Fig. 2b). However, both methods give
comparable results for the Sidik et al.8 genome-wide library
(Fig. 2a, b). We therefore recommend using DEseq2 for
normalisation of smaller libraries, but for larger libraries either
method provides reproducible results. We then used the
correlation between datasets to assess parameters that correlate
with non-reproducible phenotype scores, such as sequencing
read counts and the median absolute deviation (MAD) across
gRNA. This analysis revealed that using the median of gRNA
lfcs generated robust data, and that removing genes with the
highest 1.5% of MAD scores would maximise correlations
across datasets while retaining most genes. These results show
that the use of dataset-appropriate normalisation and MAD
thresholding provides robust fitness score calculations for
small-scale libraries.
When comparing lfcs between the 200, 800 and 3200 libraries,
we observed a shift in the 3200 compared to the 200 and 800
(Fig. 2c). This is likely a reflection of the DEseq2 normalisation,
which assumes that the majority of a population do not change
and centres on the median. Thus, the proportion of essential
genes in a library can affect the positioning of zero lfc. While this
has no bearing on the comparison of two conditions with similar
median lfcs, it needs to be taken into account for experiments
where a substantial proportion of gene lfcs change and shift the
median. To allow for an accurate comparison between datasets we
chose 25 genes present in our 3200 library that had a lfc close to
zero (0 ± 0.2) in the Sidik et al.8 dataset as a reference point. We
then shifted the lfc from the 3200 library such that the median
score of these 25 gene lfcs was set to zero. This correctly aligned
the lfcs across library sizes (Fig. 2c).
Ranked plots of gene lfcs demonstrated that control essential
genes (CDPK1, eIF4a, RON4 and MYOA) displayed the expected
negative lfcs, while non-essential controls did not (Fig. 2d). The
library size did not substantially influence gRNA behaviour
(Fig. 2e) and our data correlated well with the Sidik et al.8
phenotypic scores (although differing lfc ranges between datasets
skews the correlation axis away from the diagonal). This
demonstrates that our optimised 3–5 gRNAs per gene are
sufficient for reproducible CRISPR screening (Fig. 2f).
In vivo CRISPR screening identifies novel virulence factors. In
pathogens, virulence factors that facilitate the interaction with the
host determine whether or not a successful infection is estab-
lished. To test whether we can infect mice with customised pools
of Toxoplasma mutants, we integrated a ~1000 gRNA library into
the type II strain PruΔhxgprt. The resulting mutant pool was
subsequently inoculated into mice at a dose of 2E5 parasites per
mouse. We reasoned that this dose would allow parasite growth
without overwhelming the mouse, while maintaining sufficient
coverage per gRNA (>200 parasites/gRNA). The library included
gRNAs targeting 16 essential genes, in addition to 133 known
(ROPs and GRAs) and predicted effector proteins19. The gRNA
library was cloned and transfected into parasites in five replicates
(Fig. 3a). Following 6 days of selection in cell culture, genomic
DNA from a subset of each of the replicates was isolated for
sequencing, and the remaining parasites were pooled for intra-
peritoneal (i.p.) infection of eight mice. Five days post infection,
the peritoneal exudate was retrieved and returned to tissue culture
for parasite expansion, genomic DNA extraction and sequencing.
High reproducibility was observed between the five indepen-
dent transfection replicates in vitro, as well as the eight
independent infections in mice (Supplementary Fig. 4A and
Supplementary Data 3). As expected, the 118 genes also contained
in the 800 gRNA library showed high correlation of in vitro lfcs
with the previous experiments (Supplementary Fig. 4B). Ranked-
order plots showed that controls behaved as expected in both
in vitro and in vivo experiments (Fig. 3b, c). The non-essential
controls GRA4, ROP38, and GRA15 showed expected phenotypes,
with over-representation of gRNA targeting GRA15 consistent
with enhanced growth in vivo20. ROP16 showed no difference in
this type II strain in either cell culture or in vivo, while ROP18,
GRA25 and GRA17 showed a negative fitness score in mice.
However, contrary to previous reports, GRA16 showed no
reduction in vivo21. Moreover, MYR1 and MYR3, which form a
translocon required to transport effectors (including GRA16) into
the host cell22,23, similarly showed no phenotype in vivo. In
addition, ROP17, which functions in translocation of effector
proteins via the MYR complex24, showed no fitness cost in our
in vivo screen. Collectively, this screening provides strong genetic
evidence that translocation of MYR-dependent proteins into the
host cell is not essential for the survival of individual parasites
within the mouse peritoneum when represented in a pool.
To identify novel genes that are important for Toxoplasma
proliferation in vivo but not in cell culture, we compared the gene
fitness scores between in vitro and in vivo samples by calculating
matched gene concordance/discordance (DISCO) scores (Fig. 3f
and Supplementary Data 3). This analysis revealed previously
unreported roles for secreted proteins in vivo when compared to
their in vitro phenotypes. gRNAs targeting the dense granule
proteins GRA12 and GRA38 were under-represented after 5 days
of growth in the mouse peritoneum compared to the inoculum,
while not required for in vitro parasite growth. Similarly, the
previously unidentified TGME49_205240, TGME49_299780 and
TGME49_289150, were identified as contributing factors to
in vivo fitness. In addition, although GRA4 has a modest negative
lfc in vivo (−0.194), the in vitro (1.078) and in vivo scores are
discordant, suggesting that it does indeed contribute to in vivo
parasite growth.
Different requirements for MYR1 in mutant pools vs. single
KO. To validate the novel virulence factors identified and
investigate the lack of an in vivo phenotype for MYR1 in our
pooled infection, we introduced gene KOs in PruΔku80 (Sup-
plementary Fig. 5). We generated KOs of GRA12 and
TGME49_289150, predicted to be essential in in vivo infection
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Fig. 2 Variable pool sizes produce reproducible CRISPR selection results. PruΔhxgprt were transfected with pCAS9-T2A-HXGPRT carrying 200, 800 or 3200
gRNA in triplicate transfections. The log 2 fold change (lfc) of the gRNA presence after 6 days growth in M/X compared to the DNA input is shown.
Normalisation of sequencing counts using either a DESeq2 or b total read count for the 200, 800 and 3200 libraries and the published Sidik et al.8 dataset.
Density plots show improved reproducibility between replicates for small libraries using DESeq2. c Overlay of 200, 800 and 3200 library gene lfcs with (solid
line) and without (dotted line) centering of the 3200 library. d Ranked-order plots showing gene lfcs for 200, 800 and 3200 gRNA libraries. Essential and non-
essential control genes are marked in red and blue, respectively. Error bars represent SEM. n= 3 technical replicates. e, f Correlation plots with Pearson’s
correlation coefficient, r, of gene lfcs show that phenotypes are reproducible e across library sizes and f correlate well with published phenotype scores.
Essential and non-essential control genes are marked in red and blue, respectively. See also Supplementary Fig. 3 and Source data in Supplementary Data 2
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from the screen, and TGME49_313440 and GRA15 as non-
essential controls (summarised in Fig. 4a). We also generated
KOs of MYR1 and ROP18 in PruΔku80 to compare the pooled
screen phenotypes with that of a homogenous gene KO. C57BL/6
mice were infected with 50,000 parasites and their survival
monitored over 14 days. While mice infected with the parental
line or the controls ΔGRA15 and ΔTGME49_313440 lost weight
and succumbed to infection (10/10, 5/5 and 8/10, respectively), all
mice survived ΔGRA12, ΔTGME49_289150 and control ΔROP18
infections (Fig. 4b, Supplementary Fig. 6). Additionally, the
ΔMYR1 line was avirulent as previously reported23, confirming
the contrasting phenotypes in pooled and single strain infections
(Fig. 4a). Mice that survive acute Toxoplasma infection develop
chronic infection with parasite cysts found in the brain. Analysis
of the brains of surviving mice from this experiment revealed a
lack of cysts in mice infected with ΔGRA12, and a reduced
number of cysts in those infected with ΔTGME49_289150 com-
pared to the two mice surviving ΔTGME49_313440 infection
(Fig. 4c). As the inocula were shown to be comparable (Supple-
mentary Fig. 6), and as enzyme-linked immunosorbent assay
(ELISA) confirms all mice were infected (Fig. 4d), this validates
GRA12 and TGME49_289150 as major virulence factors in mice,
although the phenotype of GRA12 appears to be more
pronounced.
Collectively, these results show a paramount role for ROP18,
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Fig. 3 In vivo CRISPR screen identifies known and novel virulence factors. a Schematic of experimental design. gRNA were picked in triplicate, combined and
used in triplicate Gibson cloning reactions. Vector pools were combined and transfected into PruΔhxgprt in five replicates. After 6 days under M/X selection,
subsets were taken for sequencing and remaining parasites were combined to generate the mouse inoculum. Eight mice were infected intraperitoneally (i.p.)
with 200,000 parasites and the parasites retrieved from the peritoneum after 5 days. Orange stars indicate samples analysed by sequencing. b, c Rank-
ordered plot of gene lfcs in vitro (b) and in vivo (c). Essential and non-essential control genes for in vitro and in vivo growth marked in red and blue,
respectively. Translocon components MYR1 and MYR3 marked in orange. Error bars represent SEM. n= 5 technical replicates. d Discordance plot showing
gene lfcs in vitro and in vivo. Colour indicates strength of discordance score. Error bars show 95% confidence range. Examples of known and newly identified
virulence factors labelled with red and black text, respectively. See also Supplementary Fig. 4 and Source data in Supplementary Data 3
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heterologous and homogenous KO populations. In contrast,
MYR1, and by extension MYR1-dependent factors (MYR
complex components and translocated proteins), appear only
important in homogenous KO populations. This suggests a
profoundly different role for these different effector proteins in
host–pathogen interaction.
Discussion
Here we present a method to perform tailored in vitro and in vivo
CRISPR screens and demonstrate its potential by identifying
novel virulence factors in Toxoplasma. We show that tailored
CRISPR gRNA vector pools of various sizes can be readily and
reproducibly generated by cloning single-stranded gRNAs into a
vector carrying Cas9 and a selectable marker. We demonstrate
that this strategy enables us to target different parasites strains
using a range of different library sizes. As such, gRNA pools
targeting only a subset of genes, such as transcription factors or
the kinome, can be easily generated to address specific biological
questions.
While we have established the system using the HXGPRT
selection marker, which requires a Δhxgprt background strain,
using an alternative marker (e.g. DHFR) would further broaden
the use of the system. Importantly, this would mean that genetic
screening could be applied to exotic Toxoplasma isolates to
address the specific host–pathogen interactions that permit dis-
ease in immunocompetent hosts.
We have uncovered limitations in this system that are likely
true for other pooled transfection-based screens, caused by the
occurrence and resulting lethality of multiple CRISPR plasmids
entering parasites simultaneously. This is important information
when designing screens, as it informs coverage calculations for
experimental setup. It will also need to be taken into considera-
tion when single-cell analysis experiments with mutant pools are
analysed or under strong selective pressure. For example, survival
screens under drug pressure, which could select for mutants for
which the gRNA plasmid is not retained. Additionally, some care
must be taken with phenotypes from large datasets. For example,
the secreted protein GRA36 is flagged as having an in vivo
phenotype, but careful analysis of the gRNA revealed that dis-
crepancies between genome annotation versions mean these
gRNA actually target a neighbouring non-secreted protein.
Despite these limitations, we have reproducibly identified known


















































































Fig. 4 Confirmation of virulence defects identified in the CRISPR pool in vivo. a In vitro and in vivo phenotype scores for genes targeted for knockout (KO)
and mouse infection. b C57BL/6 mice were infected intraperitoneally (i.p.) with 50,000 tachyzoites of the parental line PruΔku80 (two experiments; n= 10
mice) and ΔGRA12 (two experiments; n= 10 mice), ΔTGME49_289150 (one experiment; n= 5 mice), ΔTGME49_313400 (two experiments; n= 10 mice)
and control strains ΔGRA15 (one experiment; n= 5 mice), ΔROP18 (one experiment; n= 5 mice) and ΔMYR1 (one experiment; n= 5 mice). ΔROP18,
ΔMYR1, ΔTGME49_289150 and ΔGRA12 were significantly different from PruΔku80 with P values of 0.0075, <0.0001, 0.0004 and <0.0001, respectively,
using the Mantel–Cox test. c Brains were isolated from surviving mice and cysts enumerated at 24 or 28 days post infection. ΔTGME49_313400 n= 2,
ΔGRA12 n= 10, ΔTGME49_289150 n= 5. P values were <0.0001 as calculated by one-way analysis of variance (ANOVA) with Tukey’s multiple
comparison test. d Serum was isolated from mice surviving acute infection and tested for antibodies against Toxoplasma-soluble antigens in an ELISA.
P values were ΔGRA12 P= 0.006, ΔTGME49_289150 P= 0.0058 and ΔTGME49_313400 P= 0.0009 compared to the naive sample as calculated by one-
way ANOVA with Tukey’s multiple comparison test. ** refers to P < 0.01, *** to P < 0.001 and **** to P < 0.0001. See also Supplementary Figs. 5 and 6.
Source data are provided as a Source Data file
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Surprisingly, this screen separated known effector proteins into
two groups: those genes required for in vivo growth within a
population of mutants (such as ROP18, GRA17 and GRA25) and
those that are required for growth in vivo when infecting as a
single mutant, but not when part of a mutant pool (such as
MYR1, MYR3, ROP17 and GRA16). Intriguingly, many of the
factors identified here as required for in vivo infection localise
within the PV or at the vacuole membrane (ROP18, GRA12,
GRA17, GRA25, GRA38, GRA39). Those factors not required for
survival in the peritoneum within a pool are either required for
translocation of parasite proteins into the host cell or are trans-
located effectors. ROP18 has multiple functions within an infec-
ted cell (targeting immunity regulated GTPases (IRGs), ATFb6,
and NFΚB) and is known to promote parasite survival25–28.
Crucially, it directly phosphorylates host IRGs preventing
destruction of the vacuole within murine cells, although this
phenotype is more pronounced in type I strains26,27. GRA17,
meanwhile, is required for parasite fitness by forming a pore in
the vacuole membrane for nutrient access29, and GRA25 deletion
causes differential cytokine secretion of infected macrophages30.
GRA12 localises within the PV31, and its strong phenotype in the
screen resembling that of ROP18 suggests a role in parasite sur-
vival or cell-autonomous immunity. Reassuringly, while this
manuscript was under review, Fox et al.32 identified an important
function for GRA12 at the PV in the resistance of Toxoplasma to
IRG mediated death32. Furthermore, the recently identified
GRA38 and GRA39 localise within the PV33 and show virulence
defects in our study, whereas the MYR1-translocated effector
TEEGR/HCE1 does not34,35.
ROP17, which appears to play a role in a ROP18/ROP5
complex acting on IRGs in the highly virulent type I strain36, does
not contribute to IRG defences in a type II strain and shows a
dose-dependent requirement for virulence37. Recently, ROP17
has been shown to be required for translocation of proteins via
the MYR complex24 and consistently does not appear to be
important in vivo in our study when part of a heterogenous
CRISPR mutant population in type II parasites. This finding
further supplements the power of our CRISPR strategy as it can
be used in all three major Toxoplasma strains to uncover strain-
specific differences in the future.
How the newly identified TGME49_205240, TGME49_289150
and TGME49_299780 function in Toxoplasma biology requires
further clarification. As we have not further investigated
TGME49_205240 and TGME49_299780 in this study, their role
in virulence needs to be confirmed. TGME49_205240 is a
multipass-transmembrane domain protein with a predicted Cleft
Lip and Palate domain of unknown function. TGME49_289150
and TGME49_299780 have no predicted functional domains.
TGME49_289150 is present with high sequence identity (>98%)
and shares synteny across the canonical type I, II and III Tox-
oplasma reference strains. Although no signal peptide is predicted
for TGME49_289150, an internal single transmembrane domain
could be functioning as a recessed signal as is the case for GRA6,
GRA37 and GRA4033,38. TGME49_289150 was also shown to be
phosphorylated only when inside host cells, a hallmark of many
proteins secreted into the host cell19. Its modest phenotype
compared to GRA12 and ROP18, however, suggests that it is not
absolutely required for the IRG defence pathway. Regardless of its
mechanism, deletion of TGME49_289150 impairs the ability of
Toxoplasma to mount a lethal infection at the doses used, sup-
porting the in vivo CRISPR screening data.
The observation that GRA16 (which targets p53 signalling21
and the MYR translocation complex, required for the majority of
transcriptional changes in the host cell39) were not required in a
pooled infection warrants further investigation. One hypothesis
is that the MYR1-dependent effectors become important later
during the disease progression, for example, during dissemina-
tion. However, unlike wild-type (WT) parasites, MYR1 KOs do
not lose weight during the onset of infection, indicating that these
mutants never establish an infection, which argues against this
hypothesis. More likely is the hypothesis that MYR1-dependent
effectors control the overall immune environment within the
host. In this case, parasites within the pool that do not carry
deletions for MYR1-dependent effectors could still exert this
function, allowing MYR1-dependent effector mutants to piggy-
back. The substantial transcriptional changes in the host cell that
are caused by MYR1-dependent effector proteins39, some of
which are counterbalancing, make it hard to predict what
immune signalling may contribute to the trans-rescue of MYR1
mutants in the pool. Targeted studies to understand why the
different effector proteins are separated in the in vivo CRISPR
screen will likely illuminate the survival strategies of Toxoplasma
in its murine host. Future studies aim to investigate the role of
MYR1 and its dependent proteins compared to those known to
act in the IRG response (ROP18, ROP5, GRA12) in Toxoplasma
survival. Whatever the distinction between these effector classes,
our results suggest that their biology can be teased apart in this
kind of pooled screening. It also suggests that this strategy may
complicate the identification of MYR1-dependent effectors in
in vivo screens. However, as MYR1 has been shown to have
profound transcriptional effects on the host cell, one could use
single-cell transcriptomics of a host cell infected with mutant
pools, which we are currently establishing.
Within the field of Toxoplasma infection, our CRISPR
screening method will allow the identification of genes required
for survival of different parasite strains in a variety of hosts, as
well as epistasis studies to identify genetic interactions between
genes, to name but a few. Furthermore, with an expanded library
of putative effectors, we predict to be able to identify more
virulence factors in the future. While we have established this
method in Toxoplasma, the format of arrayed single-stranded
oligonucleotides for versatile pooled gRNA libraries and the
analysis of smaller library screens will be advantageous in a range
of experimental setups and model systems.
Methods
Cell culture and parasite strains. Primary HFFs (ATCC) were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) with 4.5 g/L glucose and
GlutaMAX-1 (Gibco) supplemented with 10% foetal bovine serum at 37 °C and 5%
CO2. Toxoplasma gondii strains RHΔhxgprt40, PruΔhxgprt (gift from Dominique
Soldati, as in ref. 40) and PruΔku80 41 were maintained by growth in confluent
HFFs and passaged every 2–3 days. Parasites were seeded 2 days prior to trans-
fection for PruΔhxgprt and PruΔku80, or 1 day for RHΔhxgprt.
Plasmid construction. pCAS9-T2A-HXGPRT was generated by introducing
Thosea asigna virus 2A-like sequence (T2A)42 and Toxoplasma HXGPRT
sequences into pSAG1::CAS9-U6::gUPRT43. All primer sequences are shown in
Supplementary Table 1. HXGPRT was amplified from pGRA44 with primers 1 and
2, and combined at equal ratios with 50 ng PacI-digested pSAG1::CAS9-U6::
gUPRT, and an oligonucleotide containing the T2A sequence (primer 3) by Gibson
assembly in a homemade reaction master mix (100 mM Tris-Cl, pH 7.5, 50 mg/ml
PEG-8000, 10 mM MgCl2, 10 mM dithiothreitol, 0.2 mM each of four dNTPs, 1
mM NAD with 0.8 U T5 exonuclease (NEB), 0.5 U Phu DN polymerase (NEB) and
80 U Taq DNA ligase (NEB)). The Gibson reaction was incubated for 60 min at
50 °C. Inverse PCR was used to insert PacI and NcoI restriction sites into the gRNA
expression locus and modify the tracrRNA sequence using primers 3 and 4 and
5 and 6, respectively. gRNA sequences were introduced into pCAS9-HXGPRT and
pSAG1::CAS9 vectors by inverse PCR with primer 4 and gRNA-specific primers
5 and 32–37. To generate an mCherry-tagged Cas9 vector, pCAS9-T2A-HXGPRT::
gUPRT excluding the GFP sequence was amplified (primers 10 and 11) and
combined with an mCherry sequence with 20 bp of homology in a Gibson reaction
as above. Plasmid sequences were verified by sequencing.
gRNA library generation. Twenty base pair gRNA sequences were designed
against the Toxoplasma ME49 genome (v7.1.31) using E-CRISP15 command line
version cld-1.4.0 2017-01-19. gRNA were filtered as per the criteria in Supple-
mentary Fig. 1 to select 5 per gene. The criteria were dropped sequentially and the
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positioning parameter relaxed from 50 to 60% of coding sequence where needed to
generate 3–5 gRNA per gene. For comparison with the Toxoplasma-type I GT1
genome, the ME49 guides for each gene were extracted from the generated large.tab
file and then compared to the ToxoDB release 41 of the GT1 genome using the
program fuzznuc from the EMBOSS suite (6.6.0) with mismatches from 0 to 3. All
of these fuzznuc files were collated into a table with the use of a custom perl script
to parse the data.
Single-stranded DNA oligonucleotides including gRNA sequences with 20 bases
of homology to either side of the pCAS9-T2A-HXGRPT integration site
(Supplementary Table 1) were ordered from Sigma-Aldrich. Note that the reverse
complement was ordered to avoid a quadruple G in the homology arm.
Oligonucleotides were resuspended in 10 mM Tris-HCl (pH 8.0), 0.1 mM EDTA
(TE) buffer to 100 μM and diluted to 0.1 μM in 384-well Echo qualified microplates
(Labcyte). For gRNA pools, 7.5–20 nl (depending on pool size) oligonucleotides
were picked in triplicate using the Echo 550 liquid handler (Labcyte). Combined
gRNA picks were incubated with 100 ng NcoI/PacI-digested pCAS9-T2A-HXGPRT
at a ratio of 10:1 in Gibson reaction mix for 1 h at 50 °C. DNA was ethanol
precipitated and resuspended in 3 μl H2O. A measure of 1.5 μl of DNA was
transformed into 20 μl MegaX DH10B T1 R electrocompetent E. coli (Invitrogen)
and allowed to recover for 1 h at 37 °C before overnight growth in 350 ml LB
Ampicillin (100 μg/ml). Plasmid DNA was purified using Macherey-Nagel
Midiprep kit and reconstituted in TE buffer.
Parasite transfection. Input DNA (single plasmid or library pool) was digested
overnight with KpnI-HF (NEB), purified by phenol–chloroform precipitation and
resuspended in P3 primary cell electroporation buffer (Lonza) to a concentration of
~1.5 μg/μl. Parasites were isolated from HFFs by syringe lysis with a 23 G needle,
pelleted at 652 × g, and resuspended in P3 buffer. 7.5E5-2E6 parasites were com-
bined with 10 μg linearised plasmid DNA in a total volume of 20 μl and electro-
porated using the 4D-Nucleofector EO115 program (Lonza). Parasites were
allowed to recover for 12 min before being added to HFF monolayers (T150). At
24 h post transfection, 50 μg/ml of mycophenolic acid (Merck) and xanthine
(Sigma) (M/X) were added to select for transfectants.
Plaque assays. To test the proportion of parasites surviving transfection, 5000
parasites were seeded onto HFF monolayers in a T25 flask 12 min after transfec-
tion. After 24 h, M/X was added and plaques were allowed to form over 8 days. To
test the proportion of UPRT KO, parasites were selected in M/X for 6 days post-
transfection and 1000 parasites seeded in T25s in M/X alone or M/X with 20 μg/ml
FUDR and grown for 6 days. For testing mouse inoculum, 10 μl of a 1:10 dilution
of the inoculum was used to infect HFF monolayers in 6-well plates. Monolayers
were fixed in ice-cold methanol for 2 min, stained with crystal violet (12.5 g crystal
violet in 125 ml ethanol mixed with 500 ml of 1% ammonium oxalate) for 10 min
and the plaques enumerated.
Antibody generation. To generate the GRA29 expression plasmid, pET-28a-
GRA29, GRA29 lacking its amino-terminal signal peptide was amplified from
Toxoplasma gDNA (prepared from 1E7 RHΔhxgprt using Qiagen Blood and Tissue
DNA extraction kit) using primers 30 and 31 (Supplementary Table 1). The
amplicon was cloned into BamHI- and NdeI-digested pET-28a(+) plasmid
(Merck) by Gibson as described above. This allowed for expression of an N-
terminal 6×His-tagged GRA29 recombinant protein in E. coli BL21 cells under the
control of T7 lac promoter. His-GRA29 was purified using Ni-NTA affinity pur-
ification under native conditions using the standard manufacturer’s protocol
(Qiagen, Hilden, Germany). Recombinant His-GRA29 was used to immunise
female New Zealand white rabbits (Covalab) for the generation of polyclonal
antibodies. To verify antibody specificity, Toxoplasma lysate was separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred onto
nitrocellulose (Bio-Rad) and probed with serum at a dilution of 1:1000 in
phosphate-buffered saline (PBS) with 3% milk and 0.1% Tween-20 (Sigma-
Aldrich). After washing, the blot was incubated with horse radish peroxidase
(HRP)-conjugated anti-rabbit secondary antibody (1:20,000, Insight Biotechnology,
cat no. 474-1506). The blot was visualised using ECL Western Blotting Detection
Reagent (GE Healthcare) for chemiluminescence imaging on an Amersham Imager
600 (GE Healthcare) and the band of the expected size was detected (Supple-
mentary Fig. 2).
Immunofluorescence. HFF monolayers were infected at a multiplicity of infection
of 1 for 24 h and fixed in 3% paraformaldehyde for 15 min. Cells were permea-
bilised in 0.1% Triton for 5 min and blocked with 2% bovine serum albumin (BSA)
before staining with rabbit anti-GRA29 (1:4000), followed by anti-rabbit Alexa
Fluor 647 (1:2000, Life Technologies, cat. no. A21244) and DAPI (4′,6-diamidino-
2-phenylindole) (1:1000 of 5 mg/ml, Sigma-Aldrich). GRA29 staining and Cas9-
GFP/Cas9-mCherry expression were counted on a Ti-E Nikon microscope.
In vitro and in vivo mutant pool selections. Four days post transfection, parasites
were syringe lysed and added to fresh HFF monolayers with 100 U/ml benzonase
(Novagen) and incubated overnight to remove traces of input DNA. Six days post
transfection, samples were taken for gDNA preparation or for mouse inoculum.
For gDNA samples, parasites were syringe lysed and passed through 5 μm filters
(Millipore), counted and at least 1E7 parasites pelleted at 3220 × g. For mouse
inoculum, parasites were filtered as above, pelleted at 652 × g and resuspended in
PBS at a concentration of 1E6 parasites/ml.
C57BL/6 mice were bred and housed under pathogen-free conditions in the
biological research facility at the Francis Crick Institute in accordance with the
Home Office UK Animals (Scientific Procedures) Act 1986. All work was approved
by the UK Home Office (project license PDE274B7D), the Francis Crick Institute
Ethical Review Panel and conforms to European Union directive 2010/63/EU. Six-
to eight-week-old C57BL/6 males were injected i.p. with 200,000 parasites in 200 μl
PBS. Five days post infection, parasites and peritoneal cells were isolated by
peritoneal lavage with 5 ml of 0.5 mM EDTA/PBS. Cells and parasites were pelleted
at 652 × g, washed with PBS and added to HFF monolayers growing in DMEM
with Pen/Strep (Thermo Fisher). Pellets for gDNA were prepared as above, after
4 days parasite growth.
gRNA amplification and sequencing. gDNA was isolated using DNeasy Blood
and Tissue kit (Qiagen) and resuspended in 100 μl H2O. gRNA sequences were
amplified by nested PCR using Kapa HiFi HotStart polymerase (Roche). PCR 1
amplified a 4 kb fragment using primers 8 and 9 with sufficient template for 500×
coverage per gRNA with a maximum of 2E5 parasites/PCR reaction in 25 μl
reaction volume (e.g. for the 800 gRNA library, gDNA corresponding to 4E5
parasites was used as a template, needing 2× PCR 1 reactions). Twelve and 18
cycles were used for plasmid DNA input, and gDNA was isolated from parasites,
respectively. The PCR product was purified using 0.6× vol of Kapa Pure beads
(Roche), and 8 μl was used as a template in each of 6× of 50 μl nested PCR 2
reactions, with primers (10 with 12–23) including Illumina adaptor and index
sequences. Twenty and 25 cycles were used for plasmid DNA input, and gDNA was
isolated from parasites, respectively. Amplicons were purified as above and mixed
at equal ratios (or taking library size into consideration) and sequenced on
HiSeq4000 with paired end 100 bp reads using the HiSeq Control Software
version 3.4.0.
Illumina sequencing analysis. Data were analysed using DEseq2 v1.20.0, R v 3.5.2
and ggplot2 v 3.1.1. Computer code used in this study is available from the cor-
responding author upon reasonable request. Following demultiplexing, gRNA
sequences were trimmed and matched to target library to assess gRNA repre-
sentation. Sequencing counts were normalised using DEseq218 with default settings
across gRNAs that corresponded to genes that had at least three non-zero gRNAs.
Thresholding for the maximum MAD across gRNAs was set by selecting the value
that gave the highest Pearson’s correlation between libraries (testing 0–20%, with
0.5% step size). A threshold removing genes with the highest 1.5% of MAD scores
were applied to all datasets. Gene lfcs were calculated per sample from the median
of gRNA lfcs and the mean of gene lfcs across replicates gives the gene phenotype.
The 3200 library was centred around zero by applying a scaling factor from
published gene phenotypes8 with a value between −0.2 to 0.2 and standard error
<0.5. Gene phenotypes between in vitro and in vivo conditions were compared in a
concordance/discordance plot with a confidence (DISCO) score (DISCO score=
abs(avg(lfcin vitro)− avg(lfcin vivo)) × abs(log 10− P value+ log 10 P value).
KO generation. A Pro-GRA1::mCherry::T2A::HXGPRT::Ter-GRA2 construct was
amplified with primers containing 40 bp homology regions to the 5′- and 3′-
untranslated regions of the target genes (primers 38–49). Fifteen micrograms of
pSAG1::CAS9 carrying gRNA against the target gene and 10 µg of purified PCR
product were co-transfected into 106–107 PruΔku80 tachyzoites. Twenty four
hours after transfection, M/X was added to select for integration of the mCherry
construct. Correct mCherry integration and loss of the WT locus were verified by
PCR using primers 50–63.
In vivo infections. Mice were infected i.p. with 50,000 parasites in 200 µl PBS on
day 0. Mice were monitored and weighed regularly for the duration of the
experiments. To determine the number of cysts in the brain of infected animals,
mice were euthanised at 24–28 days post infection. The brain was homogenised in
1 ml PBS and stained with Rhodamine-conjugated Dolichos Biflorus agglutinin
(1: 2000; Vector Laboratories, cat. no. RL-1032) for 1 h at room temperature.
Fluorescently labelled cysts were counted using a Ti-E Nikon microscope. For
serum samples, jugular vein blood was drained into blood serum collection tubes
(SAI, Infusion technologies) and allowed to clot at room temperature for 30 min,
before the tubes were centrifuged at 1500 × g for 10 min. Serum was collected and
stored at −20 °C until analysis. Data were analysed in GraphPad Prism v7. Survival
curve analysis was used with the Mantel–Cox test for each KO line compared to
PruΔku80. For cyst count analysis, a one-way analysis of variance (ANOVA) with
Tukey’s multiple comparison test was used.
Toxoplasma serum antibody ELISA. To prepare Toxoplasma-soluble antigens
(TSAs), parasites were syringe lysed, washed once with PBS and adjusted to 1 × 108
tachyzoites/ml with PBS containing protease inhibitors (cOmplete mini, Roche).
Parasites were lysed by five freeze–thaw cycles (liquid nitrogen/37 °C), followed by
ultrasound sonication on ice (five 60 Hz cycle for 1 min each). Samples were
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centrifuged at 10,000 × g for 30 min at 4 °C before supernatants were collected and
protein content was determined using the BCA Protein Assay kit (Pierce) following
the manufacturer’s instructions. To detect Toxoplasma antibodies in murine serum
samples, 96-well plates (flat bottom, high-binding) were coated overnight with
2 µg/ml TSA at 4 °C. Plates were washed with PBS/0.05% Tween-20 (v/v) (PBS-T)
before blocking with 1% BSA (w/v) in PBS. Bound antigens were incubated with
murine sera diluted 1/10 in 1% BSA/PBS, washed three times with PBS-T and
bound antibodies detected by incubation with anti-mouse immunoglobulins (HRP
conjugate, Dako, cat. no. P0260) diluted 1:1000 in 1% BSA/PBS. All incubation
steps were 2 h at room temperature. Finally, plates were washed three times with
PBS-T and developed by adding TMB substrate solution (Thermo Fisher). The
TMB reaction was stopped by adding 2 N sulphuric acid and the absorbance was
measured (OD450 minus OD540) using the VersaMaxTM Microplate Reader with
the SoftMax® Pro Software. Data were analysed in GraphPad Prism 7 with a one-
way ANOVA with Tukey’s multiple comparison test.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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